Loss of RKIP expression during the carcinogenic evolution of endometrial cancer

Imagem de Miniatura
Arquivos
art_Longatto-Filho_Loss_of_RKIP_expression_during_the_carcinogenic_evolution_2012.PDF (496.51 KB)
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2012
Editora
BMJ PUBLISHING GROUP
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Martinho, Olga
Faloppa, Carlos Chaves
Neto, Cristovam Scapulatempo
Baiocchi, Glauco
da Cunha, Isabela Werneck
Soares, Fernando Augusto
Tavares Guerreiro Fregnani, Jose Humberto
Reis, Rui Manuel
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF CLINICAL PATHOLOGY, v.65, n.2, p.122-128, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims Endometrial cancer is one of the most common cancers in women worldwide, but there is a lack of diagnostic markers for early detection of these tumours. The raf kinase inhibitory protein (RKIP) negatively regulates the Raf/MEK/ERK pathway, and the downregulation of RKIP is associated with tumour progression and metastasis in several human neoplasms. The aim of this study was to assess the expression levels of RKIP in endometrial cancer and determine whether this expression correlates with clinical outcome in these patients. Methods Tissue microarrays constructed using tissue samples from 209 endometrial adenocarcinomas, 49 endometrial polyps and 48 endometrial hyperplasias were analysed for RKIP expression by immunohistochemistry. Results The authors found that RKIP expression decreases significantly during malignant progression of endometrial cancer; it is highly expressed in non-neoplastic tissues (polyps 79.6%; hyperplasias 87.5%) and expressed at very low levels in endometrioid adenocarcinomas (29.7%). No correlations were observed between RKIP expression, clinicopathological data and survival. Conclusion This study demonstrated for the first time that RKIP expression is lost during the carcinogenic evolution of endometrial tumours and that the loss of RKIP expression is associated with a malignant phenotype. Functional studies are needed to address the biological role of RKIP downregulation in endometrial cancer.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/5035
Referências
  1. Abal M, 2007, CLIN TRANSL ONCOL, V9, P272, DOI 10.1007/s12094-007-0054-z
  2. Akaishi J, 2006, ANTICANCER RES, V26, P4437
  3. Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499
  4. Al-Mulla F, 2008, J CLIN PATHOL, V61, P524, DOI 10.1136/jcp.2007.046987
  5. Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214
  6. Beach S, 2008, ONCOGENE, V27, P2243, DOI 10.1038/sj.onc.1210860
  7. Blechschmidt K, 2007, DIAGN MOL PATHOL, V16, P222
  8. Castellvi J, 2009, HUM PATHOL, V40, P1418, DOI 10.1016/j.humpath.2008.12.019
  9. Chatterjee D, 2008, CLIN CANCER RES, V14, P2994, DOI 10.1158/1078-0432.CCR-07-4496
  10. Chen Y, 2008, J PROTEOME RES, V7, P5254, DOI 10.1021/pr800602c
  11. Chia VM, 2007, INT J GYNECOL CANCER, V17, P441, DOI 10.1111/j.1525-1438.2007.00790.x
  12. Colas E, 2011, INT J CANCER, V129, P2435, DOI 10.1002/ijc.25901
  13. Doll A, 2008, J STEROID BIOCHEM, V108, P221, DOI 10.1016/j.jsbmb.2007.09.020
  14. Dutt A, 2009, BRIT J CANCER, V101, P1220
  15. Dutt A, 2009, BRIT J CANCER, V101, P1218, DOI 10.1038/sj.bjc.6605301
  16. Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015
  17. Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319
  18. Fu Z, 2003, J NATL CANCER I, V95, P878
  19. Gimenez M, 2010, PROTEOMICS, V10, P2812, DOI 10.1002/pmic.200900722
  20. Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43
  21. Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283
  22. Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173
  23. Hipp S, 2009, J CELL MOL MED, V13, P3858, DOI 10.1111/j.1582-4934.2008.00526.x
  24. Hipp S, 2008, CLIN EXP METASTAS, V25, P679, DOI 10.1007/s10585-008-9149-3
  25. Houben R, 2006, J INVEST DERMATOL, V126, P1135, DOI 10.1038/sj.jid.5700170
  26. Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
  27. Keller ET, 2004, BIOCHEM PHARMACOL, V68, P1049, DOI 10.1016/j.bcp.2004.04.024
  28. Kim HS, 2010, ENDOCR PATHOL, V21, P253, DOI 10.1007/s12022-010-9131-x
  29. KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403
  30. Lax SF, 2004, VIRCHOWS ARCH, V444, P213, DOI 10.1007/s00428-003-0947-3
  31. Li HZ, 2008, MOL CANCER RES, V6, P917, DOI 10.1158/1541-7786.MCR-08-0093
  32. Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158
  33. Maresch J, 2011, CANCER-AM CANCER SOC, V117, P2499, DOI 10.1002/cncr.25799
  34. Martinho O, 2009, VIRCHOWS ARCH, V455, P277, DOI 10.1007/s00428-009-0821-z
  35. Meyer LA, 2009, CANCER CONTROL, V16, P14
  36. Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8
  37. Mizumoto Y, 2007, CANCER SCI, V98, P652, DOI 10.1111/j.1349-7006.2007.00445.x
  38. Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6
  39. Okuda T, 2010, OBSTET GYNECOL INT, V2010
  40. Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012
  41. Sherman ME, 2000, MODERN PATHOL, V13, P295, DOI 10.1038/modpathol.3880051
  42. Vergote I, 2011, LANCET ONCOL, V12, P4, DOI 10.1016/S1470-2045(10)70280-1
  43. Villavicencio A, 2010, GYNECOL ONCOL, V117, P96, DOI 10.1016/j.ygyno.2009.12.022
  44. Wu K, 2009, CRIT REV IMMUNOL, V29, P241
  45. Xu YF, 2010, J HEPATOL, V53, P872, DOI 10.1016/j.jhep.2010.05.019
  46. Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000
  47. Yeung K, 1999, NATURE, V401, P173
  48. Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001
  49. Yurkovetsky Z, 2007, GYNECOL ONCOL, V107, P58, DOI 10.1016/j.ygyno.2007.05.041
  50. Zaravinos A, 2009, CELL CYCLE, V8, P1402, DOI 10.4161/cc.8.9.8308
  51. ZARAVINOS A, 2011, PATHOL ONCOL RES, V17, P181, DOI DOI 10.1007/S12253-010-9295-1
  52. Zhang LZ, 2004, SURGERY, V136, P708, DOI 10.1016/j.surg.2003.12.013
  53. Zlobec I, 2008, CLIN CANCER RES, V14, P143, DOI 10.1158/1078-0432.CCR-07-1380

Coleções
Artigos e Materiais de Revistas Científicas - LIM/14